In the cases of PV- or ET-related thrombosis, antiplatelet treatment is usually sufficient, combined with specific hematological treatment such as hydroxyurea or JAK-2-specific inhibitors (13). This evidence concerns the gene JAK2 and deep vein thrombosis.